SEC Filing: Form 4
Statement of changes in beneficial ownership of securities
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE’s management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025. Conference Presentation Details: Fireside Chat Timing: Thursday, March 27, 2025, at 11:00 am ET Registration: Webcast Link A webcast replay will be available on the VYNE website for 90 days following…
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., March 06, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the fourth quarter and year ended December 31, 2024, and provided a business update. “Based on our significant progress in 2024, we are now positioned to announce…